Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.8
4.4
Journals
Cancers
Special Issues
Clinical Features and Molecular Pathology of Melanomas
cancers-logo
Submit to Cancers Review for Cancers Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Clinical Features and Molecular Pathology of Melanomas

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (30 April 2025) | Viewed by 5183

Special Issue Editors

Prof. Dr. Paola Savoia

E-Mail Website
Guest Editor
Dermatology Unit, Department of Health Sciences (DiSS), School of Medicine, Università del Piemonte Orientale (UPO), Via Solaroli 17, 28100 Novara, Italy
Interests: melanoma; non-melanoma skin cancer; photoaging; cutaneous lymphomas
Special Issues, Collections and Topics in MDPI journals
Dr. Elisa Zavattaro

E-Mail Website
Guest Editor
Department of Health Science, University of Eastern Piedmont, 13100 Novara, Italy
Interests: non-melanoma skin cancer; field cancerization; organ transplant recipients; melanoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The constant increase in new diagnoses of melanoma and the potential aggressiveness of this neoplasm make it essential to fully comprehend its biological behavior.

This Special Issue aims to collect high-quality scientific papers that deepen the clinical, histopathological and molecular characteristics, potentially correlating the prognosis of patients with melanoma, which could deepen our knowledge regarding this pathology. Identifying possible new prognostic factors could facilitate the construction of personalized follow-up schedules and contribute to identifying patients who may benefit from adjuvant treatments, with a view to rationalizing healthcare resources.

This Special Issue will include scientific papers of high scientific resonance; publications will be considered for research articles or reviews.

You may choose our Joint Special Issue in Dermato.

Prof. Dr. Paola Savoia
Dr. Elisa Zavattaro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • biological behavior
  • prognosis
  • clinical and histological prognostic factors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

35 pages, 6552 KB  
Article
Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma
by Magdalena Kuras, Lazaro Hiram Betancourt, Runyu Hong, Leticia Szadai, Jimmy Rodriguez, Peter Horvatovich, Indira Pla, Jonatan Eriksson, Beáta Szeitz, Bartłomiej Deszcz, Charlotte Welinder, Yutaka Sugihara, Henrik Ekedahl, Bo Baldetorp, Christian Ingvar, Lotta Lundgren, Henrik Lindberg, Henriett Oskolas, Zsolt Horvath, Melinda Rezeli, Jeovanis Gil, Roger Appelqvist, Lajos V. Kemény, Johan Malm, Aniel Sanchez, Attila Marcell Szasz, Krzysztof Pawłowski, Elisabet Wieslander, David Fenyö, Istvan Balazs Nemeth and György Marko-Vargaadd Show full author list remove Hide full author list
Cancers 2025, 17(5), 832; https://doi.org/10.3390/cancers17050832 - 27 Feb 2025
Cited by 2 | Viewed by 1546
Abstract
Background: Melanoma is a highly heterogeneous disease, and a deeper molecular classification is essential for improving patient stratification and treatment approaches. Here, we describe the histopathology-driven proteogenomic landscape of 142 treatment-naïve metastatic melanoma samples to uncover molecular subtypes and clinically relevant biomarkers. Methods: [...] Read more.
Background: Melanoma is a highly heterogeneous disease, and a deeper molecular classification is essential for improving patient stratification and treatment approaches. Here, we describe the histopathology-driven proteogenomic landscape of 142 treatment-naïve metastatic melanoma samples to uncover molecular subtypes and clinically relevant biomarkers. Methods: We performed an integrative proteogenomic analysis to identify proteomic subtypes, assess the impact of BRAF V600 mutations, and study the molecular profiles and cellular composition of the tumor microenvironment. Clinical and histopathological data were used to support findings related to tissue morphology, disease progression, and patient outcomes. Results: Our analysis revealed five distinct proteomic subtypes that integrate immune and stromal microenvironment components and correlate with clinical and histopathological parameters. We demonstrated that BRAF V600-mutated melanomas exhibit biological heterogeneity, where an oncogene-induced senescence-like phenotype is associated with improved survival. This led to a proposed mortality risk-based stratification that may contribute to more personalized treatment strategies. Furthermore, tumor microenvironment composition strongly correlated with disease progression and patient outcomes, highlighting a histopathological connective tissue-to-tumor ratio assessment as a potential decision-making tool. We identified a melanoma-associated SAAV signature linked to extracellular matrix remodeling and SAAV-derived neoantigens as potential targets for anti-tumor immune responses. Conclusions: This study provides a comprehensive stratification of metastatic melanoma, integrating proteogenomic insights with histopathological features. The findings may aid in the development of tailored diagnostic and therapeutic strategies, improving patient management and outcomes. Full article
(This article belongs to the Special Issue Clinical Features and Molecular Pathology of Melanomas)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 1220 KB  
Review
Acral Melanoma in Skin of Color: Current Insights and Future Directions: A Narrative Review
by Emily R. Nadelmann, Ajay K. Singh, Matteo Abbruzzese, Oluwaseyi O. Adeuyan, Divya B. Kenchappa, Katherine Kovrizhkin, Michelle Lightman, Avishai Samouha, Kevin L. Tao, Jaewon Yun, Tian R. Zhu, Beth N. McLellan and Yvonne M. Saenger
Cancers 2025, 17(3), 468; https://doi.org/10.3390/cancers17030468 - 30 Jan 2025
Cited by 4 | Viewed by 3009 | Correction
Abstract
Introduction: Acral lentiginous melanoma (ALM), a rare subtype, accounts for 2–3% of melanoma cases, primarily affecting the palms, soles, and nail beds and disproportionately affects people of color. This review focuses on clinical insights into ALM and its management, with a focus [...] Read more.
Introduction: Acral lentiginous melanoma (ALM), a rare subtype, accounts for 2–3% of melanoma cases, primarily affecting the palms, soles, and nail beds and disproportionately affects people of color. This review focuses on clinical insights into ALM and its management, with a focus on race and ethnicity. Methods: A comprehensive literature search was conducted in public databases using the search term “acral melanoma,” and studies focusing on epidemiology, clinical presentation, and treatment outcomes of ALM in various racial and ethnic groups were reviewed. Results: Significant disparities in ALM outcomes exist across racial and ethnic groups, with African, Hispanic, and Asian individuals presenting with thicker, more advanced tumors at diagnosis. These populations encounter unique challenges, including limited access to dermatologic care, under-recognition of melanoma presentation in darker skin types, and socioeconomic barriers leading to delayed diagnosis and treatment. Surgical management may require specialized approaches, such as partial amputation for subungual melanomas. Additionally, there is uncertainty regarding the tumor immune microenvironment (TME) in ALM, with some studies suggesting that it might be less favorable, resulting in a lower response to immunotherapy. Conclusions: ALM affects diverse populations, and the impact of ethnic and racial origin on ALM biology is largely unknown. Addressing disparities in ALM outcomes among racial and ethnic groups is critical for improving patient care. Increased awareness of melanoma risk in individuals with darker skin can significantly impact early detection and treatment. Future research should focus on the genetic and biological factors contributing to morbidity and mortality in ALM patients. Full article
(This article belongs to the Special Issue Clinical Features and Molecular Pathology of Melanomas)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop